ClinicalTrials.gg
CompletedNCT04820309Updated Sep 17, 2025Results posted

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules in Schizophrenia, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 117 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
566
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
Largest of 20
566 · median 178
Started
2021
with 3 others
Phase 3
14 of 20
4 open now
Registered
5th of 20
by date
Lead sponsor
7 of 20
Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Among the 20 studies testing xanomeline in Schizophrenia, this one has the largest enrollment, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 5th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in de novo subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5) schizophrenia. In this OL study, all subjects will receive KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) for up to 52 weeks. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with a DSM-5 diagnosis of schizophrenia. The secondary objective of this study is to assess the long-term efficacy and characterize the pharmacokinetics of xanomeline and trospium after administration of KarXT.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is aged 18 to 65 years at screening.
  2. Subject is capable of providing .

    1. A signed informed consent form (ICF) must be provided before any study assessments are performed.
    2. Subject must be fluent in (oral and written) the language of the ICGF to consent.
  3. Subject has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the (American Psychiatric Association 2013) criteria and confirmed by Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorder Studies (MINI) version 7.0.2.
  4. Subject has not required psychiatric hospitalization, acute crisis intervention, or other increase in level of care due to symptom exacerbation within 8 weeks of screening and is psychiatrically stable in the opinion of the investigator.
  5. PANSS total score ≤ 80 at screening and Baseline Visit B (Day 0).
  6. Clinical Global Impression - Severity (CGI-S) score of ≤ 4 at screening and Baseline Visit B (Day 0).
  7. At the time of screening, or at any time within the 30 days prior to screening, the subject must have received an oral antipsychotic medication daily at a dose and frequency consistent with the drug label.
  8. In the opinion of the investigator, it is clinically appropriate for the subject to discontinue current antipsychotic therapy and initiate experimental treatment with KarXT.
  9. Subject is willing and able, in the opinion of the investigator, to discontinue all antipsychotic medications prior to baseline visit.
  10. Subject has an identified reliable informant willing to be able to address some questions related to certain study visits, if needed. An informant may not be necessary if the subject has been the patient of the investigator for ≥1 year.
  11. At Day 0, subject will have been off lithium therapy for at least 2 weeks and must have discontinued all oral antipsychotic medications.
  12. Subjects taking a long-acting injectable antipsychotic could not have received a dose of medication for at least 12 weeks (24 weeks for paliperidone palmitate) before Day 0.
  13. must be ≥ 18 and ≤ 40 kg/m2.
  14. Subject resides in a stable living situation and is anticipated to remain in a stable living situation for the duration of study enrollment, in the opinion of the investigator.
  15. Women of or men with sexual partners of childbearing potential must be willing and able to use at least 1 highly effective method of during the study and for at least 30 days after the last dose of KarXT. Sperm donation is not allowed for 30 days after the final dose of KarXT.

Exclusion criteria

Exclusion Criteria:

  1. Any primary disorder other than schizophrenia within 12 months before screening (confirmed using MINI version 7.0.2 at screening).
  2. Subject has a history of moderate to severe alcohol use disorder or a substance (other than nicotine or caffeine) use disorder within the past 12 months or a positive urine drug screen (UDS) for a substance other than cannabis at screening or baseline.
  3. History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results
  4. Subject has (HIV), cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on either medical history or liver function test results.
  5. History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma
  6. History of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months
  7. Risk for suicidal behavior during the study as determined by the investigator's clinical assessment and Columbia-Suicide Severity Rating Scale (C-SSRS).
  8. Clinically significant abnormal finding from the physical examination, medical history, , or clinical laboratory results at screening.
  9. Subjects cannot currently (within 5 half-lives before Day 0) be receiving monoamine oxidase inhibitors, anticonvulsants, tricyclic antidepressants, centrally active anticholinergics, or any other psychoactive medications other than daily antipsychotic maintenance therapy. As-needed anxiolytics and/or sleep aids are permitted. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors taken at stable dose may be permitted.
  10. Subject has a history of treatment resistance to schizophrenia medications defined as failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) within the past 12 months or having received clozapine within the past 3 years
  11. Pregnant, lactating, or less than 3 months postpartum.
  12. If, in the opinion of the investigator (and/or Sponsor), subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the investigator (and/or Sponsor), may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements.
  13. Subjects has tested positive for coronavirus disease 2019 (COVID-19) within 2 weeks of screening.
  14. Subject has extreme concerns relating to global pandemics, such as COVID-19, that preclude study participation.
  15. Subject has had psychiatric hospitalization(s) for more than 30 days (cumulative) within the 6 months before screening.
  16. Subject has prior exposure to KarXT.
  17. Risk of violent or destructive behavior.
  18. Current involuntary hospitalization or incarceration.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
566 participants (actual)

Study arms

  • Experimental
    KarXT

    Drug: Xanomeline and Trospium Chloride Capsules

Interventions

  • DrugXanomeline and Trospium Chloride Capsules

    Drug pages: Xanomeline · Trospium chloride

    Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.

    Also known as: KarXT

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

    Time frame: From time of consent to end of study (approximately 400 days)

Secondary outcomes

  1. Number of Participants With Serious Treatment Emergent Adverse Events (STEAEs)

    An SAE is any untoward medical occurrence, in the view of either the investigator or sponsor, that results in death; is life-threatening; results in inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity, and/or; is a congenital anomaly/birth defect using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

    Time frame: From time of consent to end of study (approximately 400 days)

  2. Number of Participants With TEAE Leading to Study Drug Discontinuation

    TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

    Time frame: From time of consent to end of study (approximately 400 days)

  3. Change From Baseline in PANSS Total Score at Week 52

    The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function and the negative symptoms are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms.

    Time frame: At baseline and week 52

  4. Change From Baseline in PANSS Positive Score at Week 52

    PANSS positive score is the sum of all PANSS 7 positive symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility.

    Time frame: At baseline and week 52

  5. Change From Baseline in PANSS Negative Score at Week 52

    PANSS negative score is the sum of all PANSS 7 negative symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The negative symptoms in schizophrenia are the diminution or loss of normal functions.

    Time frame: At baseline and week 52

  6. Change From Baseline in PANSS Marder Factor Negative Score at Week 52

    PANSS Marder factor score is a subscale of the PANSS; the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom subscale. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions.

    Time frame: At baseline and week 52

  7. Change From Baseline in Clinical Global Impressions-severity (CGI-S) Score Week 52

    Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness.

    Time frame: At baseline and week 52

  8. Percentage of Participants With a ≥30% Reduction in PANSS Total Score at Week 52

    A PANSS responder is defined as a participant with a reduction from baseline of at least a 30% improvement at Week 52 in the PANSS total score. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms.

    Time frame: At baseline and week 52

  9. Number of Participants With Adverse Events of Special Interest (AESI)

    LFT elevations, inclusive of drug-induced liver injury (DILI) and symptomatic orthostasis including syncope (a transient loss of consciousness or fainting) is to be captured as an AESI and reported as such. Non symptomatic orthostasis will not be reported as an AESI. Any such AESI due to any cause, whether or not related to KarXT, must be reported within 24 hours of occurrence or when the investigator becomes aware of the event.

    Time frame: From time of consent to end of study (approximately 400 days)

  10. Number of Participants With Anticholinergic and Procholinergic Symptoms

    The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.

    Time frame: From time of consent to end of study (approximately 400 days)

  11. Change From Baseline in Simpson-Angus Rating Scale (SAS)

    The Simpson-Angus Rating Scale (SAS) is a clinical tool used to assess the severity of extrapyramidal symptoms (EPS), which are drug-induced movement disorders often associated with antipsychotic medications. The scale consists of 10 items, each rated from 0 (none) to 4 (severe), with a total score range of 0 to 40. Higher scores indicate more severe symptoms. The SAS helps clinicians monitor and manage EPS in patients, guiding treatment decisions to minimize these side effects.

    Time frame: From time of consent to end of study (approximately 400 days)

  12. Change From Baseline in Barnes Akathisia Rating Scale (BARS)

    The BARS for akathisia is a rating scale used to assess the severity of drug-induced akathisia, or restlessness, involuntary movements and inability to sit still. The range of scores is 0 to 14, with higher scores indicating greater severity.

    Time frame: From time of consent to end of study (approximately 400 days)

  13. Change From Baseline in Total Abnormal Involuntary Movement Scale (AIMS)

    The Abnormal Involuntary Movement Scale (AIMS) is a tool used to assess the severity of tardive dyskinesia and other involuntary movements, often caused by antipsychotic medications. It includes 12 items, with the first 10 focusing on specific body areas and movement severity, rated from 0 (none) to 4 (severe). The total score ranges from 0 to 28, with higher scores indicating more severe symptoms. AIMS helps clinicians monitor and manage these movement disorders, guiding treatment adjustments to reduce side effects.

    Time frame: From time of consent to end of study (approximately 400 days)

  14. Change From Baseline in Body Mass Index (BMI)

    BMI is a person's weight in kilograms divided by the square of height in meters. Baseline is defined as measurements taken at screening.

    Time frame: From time of consent to end of study (approximately 400 days)

  15. Change From Baseline in Waist Circumference

    The change in waist circumference in centimeters from baseline. Baseline is defined as measurements taken at screening.

    Time frame: From time of consent to end of study (approximately 400 days)

  16. Change From Baseline in Blood Pressure Values

    The change from baseline in orthostatic diastolic and systolic blood pressure measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.

    Time frame: From time of consent to end of study (approximately 400 days)

  17. Change From Baseline in Heart Rate

    The change from baseline in orthostatic heart rate measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.

    Time frame: From time of consent to end of study (approximately 400 days)

  18. Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

    Laboratory assessments include: * Hematology * Serum chemistry * Urinalysis * HbA1c * Prolactin levels * Coagulation studies * Viral Serology * Pregnancy test

    Time frame: From time of consent to end of study (approximately 400 days)

  19. Number of Participants With Clinically Significant Changes in 12 Lead Electrocardiogram

    An electrocardiogram (ECG) measures electrical activity of the heart to detect cardiac problems.

    Time frame: From time of consent to end of study (approximately 400 days)

  20. Number of Participants With Clinically Significant Changes in Physical Examination

    A complete physical examination (body temperature, general appearance, head/eyes/ears/nose/throat \[HEENT\], examination of thorax and abdomen, assessment of cardiac, musculoskeletal, and circulatory systems, palpations for lymphadenopathy, and limited neurological examination) will be performed. A targeted physical examination includes at a minimum body temperature, a check of general appearance, as well as examination of organ systems that are relevant to the investigator based on review of the participant's reported AEs, review of systems, or concomitant medication use. These also include symptom-driven physical examinations which will be performed as clinically indicated at any study visit.

    Time frame: From time of consent to end of study (approximately 400 days)

  21. Number of Participants With Suicidal Ideation Based on the Columbia Suicide Severity Rating Scale (C-SSRS)

    The Columbia Suicide Severity Rating Scale (C-SSRS) is a tool used to assess the severity and immediacy of suicidal ideation and behavior. It covers suicidal thoughts, plans, and actions, including the frequency, intensity, and context of these behaviors. The C-SSRS does not use a numerical scoring system like some other assessment tools. Instead, it categorizes the severity of suicidal ideation and behavior based on specific criteria. The scale helps clinicians identify individuals at risk of suicide and monitor changes over time, guiding treatment decisions and ensuring safety. It is quick and easy to administer, making it useful in various clinical and research settings.

    Time frame: From time of consent to end of study (approximately 400 days)

07

Results

Posted Sep 17, 2025

Participant flow

Participant flow — Overall Study
MilestoneKarXT
Started566
Completed277
Not completed289
Withdrew: Adverse event96
Withdrew: Ineligible for further treatment according to inclusion/exclusion criteria1
Withdrew: Consent withdrawn93
Withdrew: Failure to adhere to protocol32
Withdrew: Alcohol or drug use6
Withdrew: Lost to follow-up46
Withdrew: Death2
Withdrew: Pregnancy1
Withdrew: Other reasons12

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsKarXT
Number of Participants With Treatment Emergent Adverse Events (TEAEs)466
SecondaryNumber of Participants With Serious Treatment Emergent Adverse Events (STEAEs)

An SAE is any untoward medical occurrence, in the view of either the investigator or sponsor, that results in death; is life-threatening; results in inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity, and/or; is a congenital anomaly/birth defect using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Count of participants · Participants
Number of Participants With Serious Treatment Emergent Adverse Events (STEAEs)
ParticipantsKarXT
Number of Participants With Serious Treatment Emergent Adverse Events (STEAEs)41
SecondaryNumber of Participants With TEAE Leading to Study Drug Discontinuation

TEAEs are defined as events with an onset date on or after the first dose of KarXT. An Adverse Event is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at baseline, worsens during the study, regardless of the suspected cause of the event using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Count of participants · Participants
Number of Participants With TEAE Leading to Study Drug Discontinuation
ParticipantsKarXT
Number of Participants With TEAE Leading to Study Drug Discontinuation100
SecondaryChange From Baseline in PANSS Total Score at Week 52

The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function and the negative symptoms are the diminution or loss of normal functions. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms.

Time frame:
At baseline and week 52
Reported as:
Mean · Score on a Scale
Change From Baseline in PANSS Total Score at Week 52
Score on a ScaleKarXT
Change From Baseline in PANSS Total Score at Week 52-5.5 ± 11.11
SecondaryChange From Baseline in PANSS Positive Score at Week 52

PANSS positive score is the sum of all PANSS 7 positive symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The positive symptoms in schizophrenia are the excess or distortion of normal function such as hallucinations, delusions, grandiosity, and hostility.

Time frame:
At baseline and week 52
Reported as:
Mean · Score on a Scale
Change From Baseline in PANSS Positive Score at Week 52
Score on a ScaleKarXT
Change From Baseline in PANSS Positive Score at Week 52-1.9 ± 3.71
SecondaryChange From Baseline in PANSS Negative Score at Week 52

PANSS negative score is the sum of all PANSS 7 negative symptom scales with a minimum score of 7 and a maximum score of 49. Higher scores indicate more severe symptoms. Participants are rated from 1 to 7 on each symptom scale. The negative symptoms in schizophrenia are the diminution or loss of normal functions.

Time frame:
At baseline and week 52
Reported as:
Mean · Score on a Scale
Change From Baseline in PANSS Negative Score at Week 52
Score on a ScaleKarXT
Change From Baseline in PANSS Negative Score at Week 52-0.8 ± 4.42
SecondaryChange From Baseline in PANSS Marder Factor Negative Score at Week 52

PANSS Marder factor score is a subscale of the PANSS; the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom subscale. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions.

Time frame:
At baseline and week 52
Reported as:
Mean · Score on a Scale
Change From Baseline in PANSS Marder Factor Negative Score at Week 52
Score on a ScaleKarXT
Change From Baseline in PANSS Marder Factor Negative Score at Week 52-1.1 ± 4.49
SecondaryChange From Baseline in Clinical Global Impressions-severity (CGI-S) Score Week 52

Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness.

Time frame:
At baseline and week 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Clinical Global Impressions-severity (CGI-S) Score Week 52
Score on a ScaleKarXT
Change From Baseline in Clinical Global Impressions-severity (CGI-S) Score Week 52-0.4 ± 0.70
SecondaryPercentage of Participants With a ≥30% Reduction in PANSS Total Score at Week 52

A PANSS responder is defined as a participant with a reduction from baseline of at least a 30% improvement at Week 52 in the PANSS total score. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. PANSS total score is the sum of all 30 items with a minimum score of 30 and a maximum score of 210. Higher scores indicate more severe symptoms.

Time frame:
At baseline and week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥30% Reduction in PANSS Total Score at Week 52
percentage of participantsKarXT
Percentage of Participants With a ≥30% Reduction in PANSS Total Score at Week 529.2
SecondaryNumber of Participants With Adverse Events of Special Interest (AESI)

LFT elevations, inclusive of drug-induced liver injury (DILI) and symptomatic orthostasis including syncope (a transient loss of consciousness or fainting) is to be captured as an AESI and reported as such. Non symptomatic orthostasis will not be reported as an AESI. Any such AESI due to any cause, whether or not related to KarXT, must be reported within 24 hours of occurrence or when the investigator becomes aware of the event.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESI)
ParticipantsKarXT
Number of Participants With Adverse Events of Special Interest (AESI)19
SecondaryNumber of Participants With Anticholinergic and Procholinergic Symptoms

The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Count of participants · Participants
Number of Participants With Anticholinergic and Procholinergic Symptoms
ParticipantsKarXT
Anticholinergic159
Procholinergic210
SecondaryChange From Baseline in Simpson-Angus Rating Scale (SAS)

The Simpson-Angus Rating Scale (SAS) is a clinical tool used to assess the severity of extrapyramidal symptoms (EPS), which are drug-induced movement disorders often associated with antipsychotic medications. The scale consists of 10 items, each rated from 0 (none) to 4 (severe), with a total score range of 0 to 40. Higher scores indicate more severe symptoms. The SAS helps clinicians monitor and manage EPS in patients, guiding treatment decisions to minimize these side effects.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Mean · Score on a Scale
Change From Baseline in Simpson-Angus Rating Scale (SAS)
Score on a ScaleKarXT
Change From Baseline in Simpson-Angus Rating Scale (SAS)0.1 ± 0.48
SecondaryChange From Baseline in Barnes Akathisia Rating Scale (BARS)

The BARS for akathisia is a rating scale used to assess the severity of drug-induced akathisia, or restlessness, involuntary movements and inability to sit still. The range of scores is 0 to 14, with higher scores indicating greater severity.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Mean · Score on a Scale
Change From Baseline in Barnes Akathisia Rating Scale (BARS)
Score on a ScaleKarXT
Change From Baseline in Barnes Akathisia Rating Scale (BARS)0.1 ± 0.58
SecondaryChange From Baseline in Total Abnormal Involuntary Movement Scale (AIMS)

The Abnormal Involuntary Movement Scale (AIMS) is a tool used to assess the severity of tardive dyskinesia and other involuntary movements, often caused by antipsychotic medications. It includes 12 items, with the first 10 focusing on specific body areas and movement severity, rated from 0 (none) to 4 (severe). The total score ranges from 0 to 28, with higher scores indicating more severe symptoms. AIMS helps clinicians monitor and manage these movement disorders, guiding treatment adjustments to reduce side effects.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Mean · Score on a Scale
Change From Baseline in Total Abnormal Involuntary Movement Scale (AIMS)
Score on a ScaleKarXT
Change From Baseline in Total Abnormal Involuntary Movement Scale (AIMS)0.1 ± 0.57
SecondaryChange From Baseline in Body Mass Index (BMI)

BMI is a person's weight in kilograms divided by the square of height in meters. Baseline is defined as measurements taken at screening.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Mean · kg/m^2
Change From Baseline in Body Mass Index (BMI)
kg/m^2KarXT
Change From Baseline in Body Mass Index (BMI)-0.761 ± 2.0108
SecondaryChange From Baseline in Waist Circumference

The change in waist circumference in centimeters from baseline. Baseline is defined as measurements taken at screening.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Mean · cm
Change From Baseline in Waist Circumference
cmKarXT
Change From Baseline in Waist Circumference-1.549 ± 7.3558
SecondaryChange From Baseline in Blood Pressure Values

The change from baseline in orthostatic diastolic and systolic blood pressure measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Mean · mmHG
Change From Baseline in Blood Pressure Values
mmHGKarXT
Supine Systolic0.1 ± 12.83
Standing Systolic-0.7 ± 12.33
Supine Diastolic0.1 ± 8.72
Standing Diastolic-0.2 ± 8.26
SecondaryChange From Baseline in Heart Rate

The change from baseline in orthostatic heart rate measured while supine and standing after 2 minutes. Baseline is defined as measurements taken at screening.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Mean · beats/min
Change From Baseline in Heart Rate
beats/minKarXT
Supine Heart Rate0.7 ± 11.43
Standing Heart Rate0.1 ± 11.22
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

Laboratory assessments include: * Hematology * Serum chemistry * Urinalysis * HbA1c * Prolactin levels * Coagulation studies * Viral Serology * Pregnancy test

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
ParticipantsKarXT
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments0
SecondaryNumber of Participants With Clinically Significant Changes in 12 Lead Electrocardiogram

An electrocardiogram (ECG) measures electrical activity of the heart to detect cardiac problems.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in 12 Lead Electrocardiogram
ParticipantsKarXT
Number of Participants With Clinically Significant Changes in 12 Lead Electrocardiogram0
SecondaryNumber of Participants With Clinically Significant Changes in Physical Examination

A complete physical examination (body temperature, general appearance, head/eyes/ears/nose/throat \[HEENT\], examination of thorax and abdomen, assessment of cardiac, musculoskeletal, and circulatory systems, palpations for lymphadenopathy, and limited neurological examination) will be performed. A targeted physical examination includes at a minimum body temperature, a check of general appearance, as well as examination of organ systems that are relevant to the investigator based on review of the participant's reported AEs, review of systems, or concomitant medication use. These also include symptom-driven physical examinations which will be performed as clinically indicated at any study visit.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Physical Examination
ParticipantsKarXT
Number of Participants With Clinically Significant Changes in Physical Examination3
SecondaryNumber of Participants With Suicidal Ideation Based on the Columbia Suicide Severity Rating Scale (C-SSRS)

The Columbia Suicide Severity Rating Scale (C-SSRS) is a tool used to assess the severity and immediacy of suicidal ideation and behavior. It covers suicidal thoughts, plans, and actions, including the frequency, intensity, and context of these behaviors. The C-SSRS does not use a numerical scoring system like some other assessment tools. Instead, it categorizes the severity of suicidal ideation and behavior based on specific criteria. The scale helps clinicians identify individuals at risk of suicide and monitor changes over time, guiding treatment decisions and ensuring safety. It is quick and easy to administer, making it useful in various clinical and research settings.

Time frame:
From time of consent to end of study (approximately 400 days)
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation Based on the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsKarXT
Wish to be dead1
Non-Specific Active Suicidal Thoughts1
Active Suicidal Ideation with any methods without intent to act0
Active Suicidal Ideation with some intent to act but without a plan1
Active Suicidal Ideation with specific plan and intent0

Adverse events

Collected over From time of consent to end of study (approximately 400 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KarXT2/566 (0.4%)41/566 (7.2%)356/566 (62.9%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventKarXT
SchizophreniaPsychiatric disorders10/566
Psychotic disorderPsychiatric disorders4/566
Abdominal painGastrointestinal disorders2/566
VomitingGastrointestinal disorders2/566
DeathGeneral disorders2/566
DizzinessNervous system disorders2/566
Angina pectorisCardiac disorders1/566
DiarrhoeaGastrointestinal disorders1/566
DyspepsiaGastrointestinal disorders1/566
COVID-19Infections and infestations1/566
Most frequent other events
Showing 10 of 12
Most frequent other events
EventKarXT
NauseaGastrointestinal disorders131/566
VomitingGastrointestinal disorders113/566
ConstipationGastrointestinal disorders102/566
HypertensionVascular disorders59/566
Dry mouthGastrointestinal disorders53/566
DiarrhoeaGastrointestinal disorders52/566
DizzinessNervous system disorders49/566
HeadacheNervous system disorders46/566
DyspepsiaGastrointestinal disorders41/566
SomnolenceNervous system disorders35/566

Baseline characteristics

Age, Continuous
Age, Continuous(Years)KarXT
Mean47.4 ± 11.76
Sex: Female, Male
Sex: Female, Male(Participants)KarXT
Female191
Male375
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)KarXT
Hispanic or Latino119
Not Hispanic or Latino443
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)KarXT
American Indian or Alaska Native1
Asian5
Native Hawaiian or Other Pacific Islander2
Black or African American389
White164
More than one race0
Unknown or Not Reported5
08

Study locations

117 sites
  • Local Institution - 011-238
    Little Rock, Arkansas 72211-3702, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Local Institution - 011-201
    Rogers, Arkansas 72758, United States
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • Local Institution - 011-240
    Anaheim, California 92805-5854, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • Clinical Innovations, Inc
    Bellflower, California 90706, United States
  • Local Institution - 011-222
    Bellflower, California 90706, United States
  • Local Institution - 011-263
    Bellflower, California 90706, United States
  • Local Institution - 011-257
    Cerritos, California 90703, United States
  • ATP Clinical Research Inc
    Costa Mesa, California 92626, United States
  • ATP Clinical Research, Inc.
    Costa Mesa, California 92626, United States
  • Local Institution - 011-206
    Culver City, California 90230, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Local Institution - 011-253
    Garden Grove, California 92845, United States
  • Local Institution - 011-202
    Glendale, California 91206-4282, United States
  • Behavioral Clinical Research, Inc.
    Glendale, California 91206, United States
  • Omega Clinical Trials
    La Habra, California 90631-3842, United States
  • Omega Clinical Trials
    La Habra, California 90631, United States
  • Alliance for Wellness dba Alliance for Research
    Long Beach, California 90807, United States
  • Alliance for Wellness
    Long Beach, California 90807, United States
  • North County Clinical Research (NCCR)
    Oceanside, California 92054, United States
  • Excell Research Inc
    Oceanside, California 92056, United States
  • Local Institution - 011-229
    Oceanside, California 92056, United States
  • Local Institution - 011-242
    Orange, California 92868, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • CNRI-Los Angeles, LLC
    Pico Rivera, California 90660, United States
  • Local Institution - 011-244
    Pico Rivera, California 90660, United States
  • CITrials
    Riverside, California 92506, United States
  • Local Institution - 011-233
    Riverside, California 92506, United States
  • CITrials
    Santa Ana, California 92705, United States
  • Local Institution - 011-251
    Santa Rosa, California 95401-4691, United States
  • Siyan Clinical Research
    Santa Rosa, California 95401, United States
  • Local Institution - 011-246
    Sherman Oaks, California 91403-1747, United States
  • Schuster Medical Research Institute
    Sherman Oaks, California 91403, United States
  • Collaborative Neuroscience Research
    Torrance, California 90502, United States
  • Local Institution - 011-252
    Torrance, California 90504, United States
  • Local Institution - 011-224
    Hallandale, Florida 33009, United States
  • Velocity Clinical Research, Hallandale Beach
    Hallandale, Florida 33009, United States
  • Local Institution - 011-261
    Hollywood, Florida 33024, United States
  • Homestead Research Institute, Inc.
    Homestead, Florida 33030, United States
  • Local Institution - 011-231
    Homestead, Florida 33030, United States
  • Local Institution - 011-203
    Miami, Florida 33122-1335, United States
  • Premier Clinical Research Institute
    Miami, Florida 33122, United States
  • Central Miami Medical Institute
    Miami, Florida 33125, United States
  • Local Institution - 011-215
    Miami, Florida 33125, United States
  • Local Institution - 011-220
    Miami, Florida 33165, United States
  • Phoenix Medical Research
    Miami, Florida 33165, United States
  • Innovative Clinical Research
    Miami Lakes, Florida 33016, United States
  • Local Institution - 011-234
    Miami Lakes, Florida 33016, United States
  • Research Centers of America at Fort Lauderdale Behavioral Health Center
    Oakland Park, Florida 33334, United States
  • Health Synergy Clinical Research
    Okeechobee, Florida 34972, United States
  • Local Institution - 011-216
    Okeechobee, Florida 34972, United States
  • Local Institution - 011-219
    Pembroke Pines, Florida 33024, United States
  • Pines Care Research Center
    Pembroke Pines, Florida 33024, United States
  • Local Institution - 011-262
    West Palm Beach, Florida 33407, United States
  • Neuroscience Research Institute
    West Palm Beach, Florida 33407, United States
  • Local Institution - 011-259
    Atlanta, Georgia 30328, United States
  • Synexus Clinical Research US, Inc.
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Local Institution - 011-237
    Atlanta, Georgia 30331, United States
  • Local Institution - 011-235
    Decatur, Georgia 30030-2549, United States
  • Local Institution - 011-204
    Chicago, Illinois 60640-5017, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • Local Institution - 011-223
    Wichita, Kansas 67214-2878, United States
  • Ascension Via Christi Research
    Wichita, Kansas 67214, United States
  • Local Institution - 011-205
    Shreveport, Louisiana 71101, United States
  • Louisiana Clinical Research
    Shreveport, Louisiana 71101, United States
  • CBH Health, LLC
    Gaithersburg, Maryland 20877, United States
  • Local Institution - 011-211
    Gaithersburg, Maryland 20877, United States
  • Local Institution - 011-232
    Ann Arbor, Michigan 48105-3205, United States
  • Michigan Clinical Research Institute PC
    Ann Arbor, Michigan 48105, United States
  • Local Institution - 011-226
    Flowood, Mississippi 39170, United States
  • Precise Research Centers
    Flowood, Mississippi 39170, United States
  • Local Institution - 011-227
    Saint Charles, Missouri 63304, United States
  • Midwest Research Group - St. Charles Psychiatric Associates
    Saint Charles, Missouri 63304, United States
  • St. Charles Psychiatric Associates/Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Arch Clinical Trials
    St Louis, Missouri 63118, United States
  • Local Institution - 011-241
    St Louis, Missouri 63141, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Local Institution - 011-239
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Local Institution - 011-230
    Berlin, New Jersey 08009, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Local Institution - 011-249
    Marlton, New Jersey 08053, United States
  • Local Institution - 011-256
    New York, New York 10036, United States
  • Manhattan Behavioral Medicine, PLLC
    New York, New York 10036, United States
  • Local Institution - 011-210
    New York, New York 10128, United States
  • The Medical Research Network, LLC
    New York, New York 10128, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Local Institution - 011-250
    Rochester, New York 14618, United States
  • Clinical Trials of America
    Hickory, North Carolina 28601, United States
  • Local Institution - 011-218
    Dayton, Ohio 45417, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Local Institution - 011-248
    North Canton, Ohio 44720, United States
  • Neuro-Behavioral Clinical Research, Inc
    North Canton, Ohio 44720, United States
  • Cincy Science
    West Chester, Ohio 45069, United States
  • Local Institution - 011-221
    West Chester, Ohio 45069, United States
  • SP Research PLLC
    Oklahoma City, Oklahoma 73112, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States

Showing the first 100 of 117 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in May 2024, 35 months.

Results were first posted in Sep 2025, 1 year 3 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 35 months is close to that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2021
First posted
Mar 29, 2021
StartActual
Jun 2, 2021
Primary completionActual
May 24, 2024
CompletionActual
May 24, 2024
Results first posted
Sep 17, 2025
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04820309
Responsible party
Sponsor
First posted
Mar 29, 2021
Start date
Jun 2, 2021
Primary completion
May 24, 2024
Completion
May 24, 2024
Results posted
Sep 17, 2025
Last update
Sep 17, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb
Inder Kaul, MD
study director · Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion